Skip to content
Clinical Trials – home
RomaniaBack to Romania

Clinical trials in Rosu – page 9

227 clinical trials in Rosu, Romania. Every trial is listed in the EU Clinical Trials Register and updated daily.

RomaniaOur site in RomaniaStudii.Clinice.ro(opens in a new tab)
Rosu at a glance
227
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

227 trials in Rosu

Open in trial search

Myelofibrosis+1

Recruiting

Study on the Effectiveness and Safety of Selinexor for Patients with Myelofibrosis and Moderate Thrombocytopenia Who Have Not Used JAK Inhibitors

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Aprepitant
  • Sponsor:Karyopharm Therapeutics Inc.

Study Comparing Mezigdomide, Bortezomib, and Dexamethasone with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Celgene Corp.

Study on THIO and Cemiplimab for Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Maia Biotechnology Inc.

Study Comparing Telisotuzumab Vedotin and Docetaxel for Adults with Previously Treated Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study to Compare Fianlimab and Cemiplimab Combination with Pembrolizumab in Patients with High-Risk Melanoma After Surgery

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Psoriasis

Recruiting

Study on Deucravacitinib for Children with Moderate to Severe Plaque Psoriasis

Investigational
Countries:RomaniaRomania
  • Participants:0–17 years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Breast cancer

Recruiting

Study on the Effectiveness of Inavolisib with Trastuzumab and Pertuzumab for Patients with HER2-Positive, HR-Positive, PIK3CA Mutant Early Breast Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Inavolisib
  • Sponsor:GBG Forschungs GmbH

Study on Human Normal Immunoglobulin and Sodium Chloride to Prevent Infections in Patients with Chronic Lymphocytic Leukemia

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Grifols Therapeutics LLC

Long-Term Follow-Up Study for Patients Treated with Idecabtagene Vicleucel or Lisocabtagene Maraleucel for Cancer

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:BMS-986515
  • Sponsor:Celgene Corp.

Study Comparing Iberdomide and Lenalidomide for Maintenance Therapy After Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Celgene Corp.

Phase 3 Study of Ivonescimab Versus Durvalumab as Consolidation Therapy in Patients with Unresectable Stage III Non‑Small Cell Lung Cancer After Chemoradiation

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Summit Therapeutics Inc.

Systemic lupus erythematosus+1

Not yet recruiting

Randomized Placebo‑Controlled Trial of Cenerimod for Efficacy and Safety in Adults with Systemic Lupus Erythematosus and Active Lupus Nephritis

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Cenerimod
  • Sponsor:Viatris Innovation GmbH

Other cities in Romania

The busiest research cities in the country

All 63 cities in Romania

Clinical research in Rosu

What the registry says about research in the country

01 Cardiovascular Disease – Atrial Fibrillation

Research in Rosu is centered on a common heart rhythm disorder that raises the chance of serious vascular events.

  • Evaluation of REGN7508 compared with standard anticoagulant therapy
  • Combined REGN7508 and REGN9933 versus placebo
  • Risk assessment of clinically relevant bleeding
  • Stroke and systemic embolism prevention for patients unsuitable for oral anticoagulation

The trials aim to expand treatment choices and lower the incidence of stroke and embolic complications in atrial fibrillation.

02 Anticoagulation Safety in Atrial Fibrillation

Ongoing studies examine how to protect patients from ischemic stroke while reducing the likelihood of major bleeding events.

  • Comparison of bleeding risk between experimental agents and apixaban
  • Evaluation of major bleeding outcomes with dual‑target therapy
  • Analysis of stroke prevention effectiveness in high‑risk cohorts
  • Safety profiling for participants unable to use conventional oral anticoagulants

Findings are expected to inform safer anticoagulation strategies for individuals living with atrial fibrillation.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.